Section Arrow
Quote
SLXN.NASDAQ
- Silexion Therapeutics Corp
Quotes are at least 15-min delayed:2026/04/21 05:55 EDT
Pre Market
Last
 1.07
-0.01 (-0.93%)
Bid
1.08
Ask
1.11
High 1.11 
Low 1.07 
Volume 63 
Regular Hours (Closed)
Last
 1.08
+0.01 (+0.93%)
Day High 
1.095 
Prev. Close
1.07 
1-M High
1.61 
Volume 
37.35K 
Bid
1.08
Ask
1.11
Day Low
1.05 
Open
1.07 
1-M Low
0.9701 
Market Cap 
4.36M 
Currency 美元 
P/E 0 
%Yield -- 
10-SMA 1.07 
20-SMA 1.17 
50-SMA 1.45 
52-W High 22.36 
52-W Low 0.656 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.96/-2.87
Enterprise Value
6.21M
Balance Sheet
Book Value Per Share
0.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.41+0.1528+59.41%0.09PE
Pre Market 0.3401 -0.0699 -17.05%
CMNDClearmind Medicine Inc.1.14+0.4204+58.42%-- 
Pre Market 0.9531 -0.1869 -16.39%
ENVBEnveric Biosciences Inc.3.65+1.83+100.55%0PE
Pre Market 3.2305 -0.4195 -11.49%
ATAIAtaiBeckley Inc4.9+0.87+21.59%-- 
Pre Market 4.97 +0.07 +1.43%
PBMPsyence Biomedical Ltd.11.3+3.7+48.68%-- 
Pre Market 11.48 +0.18 +1.59%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.